Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

KMPH

KemPharm (KMPH)

KemPharm Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:KMPH
DataHoraFonteTítuloCódigoCompanhia
25/06/202418:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KMPHKemPharm Inc
25/06/202418:11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KMPHKemPharm Inc
29/04/202408:49Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KMPHKemPharm Inc
10/04/202417:23Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KMPHKemPharm Inc
10/04/202408:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KMPHKemPharm Inc
09/04/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KMPHKemPharm Inc
03/04/202417:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KMPHKemPharm Inc
01/04/202418:27Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KMPHKemPharm Inc
26/06/202317:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KMPHKemPharm Inc
15/05/202318:35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KMPHKemPharm Inc
15/05/202317:23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KMPHKemPharm Inc
17/04/202317:26Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:KMPHKemPharm Inc
16/03/202307:02Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prrn14a)NASDAQ:KMPHKemPharm Inc
15/03/202308:04Edgar (US Regulatory)Proxy Statment - Contested Solicitations (definitive) (defc14a)NASDAQ:KMPHKemPharm Inc
13/03/202317:30Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:KMPHKemPharm Inc
07/03/202319:31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:KMPHKemPharm Inc
07/03/202319:28Edgar (US Regulatory)Annual Report (10-k)NASDAQ:KMPHKemPharm Inc
01/03/202309:43GlobeNewswire Inc.Zevra Therapeutics Begins Trading as ZVRANASDAQ:KMPHKemPharm Inc
28/02/202310:00GlobeNewswire Inc.Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)NASDAQ:KMPHKemPharm Inc
27/02/202318:30GlobeNewswire Inc.Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary ProxyNASDAQ:KMPHKemPharm Inc
27/02/202318:11Edgar (US Regulatory)Proxy Statement - Contested Solicitations (preliminary) (prec14a)NASDAQ:KMPHKemPharm Inc
27/02/202309:30GlobeNewswire Inc.Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 ResultsNASDAQ:KMPHKemPharm Inc
24/02/202309:30GlobeNewswire Inc.Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023NASDAQ:KMPHKemPharm Inc
23/02/202309:30GlobeNewswire Inc.Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023NASDAQ:KMPHKemPharm Inc
22/02/202310:50GlobeNewswire Inc.CORRECTION – KemPharm Announces Corporate Name Change to Zevra TherapeuticsNASDAQ:KMPHKemPharm Inc
22/02/202309:30GlobeNewswire Inc.KemPharm Announces Corporate Name Change to Zevra TherapeuticsNASDAQ:KMPHKemPharm Inc
31/01/202309:30GlobeNewswire Inc.KemPharm Enhances Senior Management TeamNASDAQ:KMPHKemPharm Inc
24/01/202309:30GlobeNewswire Inc.KemPharm Issues Letter to ShareholdersNASDAQ:KMPHKemPharm Inc
18/01/202309:30GlobeNewswire Inc.KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and AdvocacyNASDAQ:KMPHKemPharm Inc
11/01/202309:30GlobeNewswire Inc.KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development OfficerNASDAQ:KMPHKemPharm Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:KMPH